[Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
The results of examination of 58 patients in the course of multiple myeloma (MM) are discussed. Prognosis for LDH, beta2-m and FNO-alpha administration was evaluated versus immunochemical pattern, tumor mass and response to different chemotherapeutic regimens. High prognostic value of serum levels of LDH, beta2 and FNO-alpha in MM patients was observed. The method may be useful in carrying out chemotherapy and detecting recurrences and chemoresistance.
Russian Research Institute of Hematology and Transfusiology, Municipal Diagnostic Center, St.Petersburg.
K M
KM
Abdulkadyrov
L V
LV
Stel'mashenko
S S
SS
Bessmel'tsev
I F
IF
Lubo-Lesnichenko
A V
AV
Sel'tser
O E
OE
Rozanova
N K
NK
Gubarenko
L N
LN
Bubnova
M M
MM
Mnuskina
A A
AA
Zhuchikhina
M N
MN
Blinov
N L
NL
Gritskevich
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*; D011237:Predictive Value of Tests; D011379:Prognosis; D001613:beta 2-Microglobulin / Q000378:metabolism
D014408:Biomarkers, Tumor; D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase